Paroxysmal Atrial Fibrillation Catheter Ablation Outcome Depends on Pulmonary Veins Anatomy

Gabriel Odozynski,1,2 Alexander Romeno Janner Dal Forno,2 Andrei Lewandowski,2 Hélcio Garcia Nascimento,2 André d’Avila2

Universidade Federal de Santa Catarina (UFSC),1 Florianópolis, SC – Brazil
Serviço de Arritmia e Marcapasso - Hospital SOS Cardio, Florianópolis, SC – Brazil

Abstract

Background: Pulmonary veins (PV) are often the trigger to atrial fibrillation (AF). Occasionally, left PVs converge on a common trunk (LCT) providing a simpler structure for catheter ablation.

Objective: To compare the clinical characteristics and outcomes of ablation in paroxysmal atrial fibrillation (PAF) of patients with or without LCT.

Methods: Case-control study of patients undergoing first-ever catheter ablation procedure for drug refractory PAF. The information was taken from patients’ records by means of a digital collection instrument, and indexed to an online database (Syscardio®). Clinical characteristics and procedures were compared between patients with or without LCT (LCT x n-LCT), adopting a level of statistical significance of 5%. The primary endpoint associated with efficacy was lack of atrial arrhythmia over the follow-up time.

Results: One hundred and seventy two patients with PAF were included in the study, 30 (17%) LCT and 142 (83%) n-LCT. The clinical characteristics, comorbidities, symptoms scale and risk scores did not differ between the groups. There was AF recurrence in 27% of PAF patients in the n-LCT group and only 10% of patients in the LCT group (OR: 3.4 p: 0.04) after a follow-up of 34 ± 17 months and 26 ± 15 months respectively.

Conclusion: Patients with a LCT have a significantly lower recurrence rate when compared to patients without this structure. It is mandatory to report the results of AF catheter ablation as a PV anatomical variation function. (Arq Bras Cardiol. 2018; 111(6):824-830)

Keywords: Atrial Fibrillation/physiopathology; Arrhythmias, Cardiac; Catheter Ablation; Pulmonary Veins/physiopathology; Electrophysiologic Techniques, Cardiac.

Introduction

The electrical activity trigger responsible for triggering paroxysmal atrial fibrillation (PAF) is often located in the pulmonary veins (PV), so that the electrical isolation of the PVs is the therapeutic mainstem in the invasive treatment of this arrhythmia.1,3

In most patients, four PV reach the left atrium. However, previous studies suggest that PV anatomical variations are related to a higher incidence of AF.1,5 The left common trunk (fusion of the 2 left PVs in a common trunk [LCT]) is the most common of the PV anatomical variations, occurring in 4 to 18% of patients undergoing catheter ablation.6 However, it is not clear whether the presence of these anatomical variations changes the outcome and the recurrence rates in the invasive treatment of PAF. As LCT can be easily identified by computed tomography (CT), knowing the clinical outcome of ablation in this population may be relevant in clinical decision-making when an ablative procedure is indicated. Therefore, the objective of this study was to compare the clinical characteristics and outcomes of patients undergoing PAF ablation with and without PV common left trunk.

Methods

Study design and participants

This is a single-center, case-control study conducted between January 2011 and December 2015, with the inclusion of patients (≥ 18 years old) undergoing the first catheter ablation procedure to treat PAF that does not respond to antiarrhythmic drugs with a minimum follow-up of 12 months. The information was collected and indexed in a digital database aimed at AF ablation (SysCardio® software). Along with CT, the presence of the LCT was confirmed through...
a 3D atrial model constructed during the procedure with an electroanatomic mapping system by (NavX®). Patients with persistent or long-term persistent AF, patients with previous ablations and AF of reversible etiology, hypertrophic cardiomyopathy, rheumatic heart disease, congenital heart disease and prior catheter ablation were excluded from the sample (Figure 1).

Procedures and ablation protocol

All procedures were performed under general anesthesia, orotracheal intubation, and invasive monitoring of blood pressure by radial or left femoral puncture, under the care of an anesthesiologist. Transseptal punctures were performed with echocardiography assistance, which was maintained throughout the procedure.

All patients underwent circumferential isolation of the PVs through a 3.5-mm tip irrigated catheter ablation without contact force measurement, using radiofrequency energy with applications of up to 35 watts and 43°C for 30-45 seconds, and demonstration of electrical VPs entrance and exit block in relation to the left atrium at the end of the isolation. After the demonstration of entrance and exit block, patients received 18 mg of IV adenosine bolus. In cases of electrical reconnection, new mapping-guided radiofrequency applications were performed until adenosine-mediated reconnection no longer occurred. The applications in the left atrium posterior wall were performed with 20 watts for up to 15 seconds, and were interrupted in case of increased esophageal temperature > 38°C. Applications to the left atrium posterior wall were monitored through an esophageal thermometer with multiple coated sensors (Circa®), and were stopped whenever there was a change in esophageal temperature above 38°C. During all procedures performed with an electroanatomical mapping system based on thoracic impedance (EnSite Navx - Abbott®), IV heparin bolus of 100mg/kg was performed, followed by continuous infusion to keep activated coagulation time between 350 and 450s.

Definitions of anatomical variants of the pulmonary veins

The vein anatomy was defined as normal when two right PV and two distinct left PV were viewed, and the presence of the left common trunk was defined when the two left PV coalesced on a path > 10 mm from before insertion into the left atrium in a common ostium (Figure 2).

Clinical follow-up

After the procedure, patients remained on antiarrhythmic drugs (propafenone, sotalol or amiodarone depending on the preference of the attending physician) for 1 month, and anticoagulant for at least 3 months regardless of CHA₂DS₂-VASc. There was a clinical follow-up of 1, 3, 6 and 12 months after the procedure with ECG and at least two continuous 5-day electrocardiographic (Holter) monitoring throughout the whole clinical follow-up. At the 10th week after ablation, patients were encouraged to undergo a 5-day Holter. Any atrial arrhythmia greater than 30 seconds duration documented after 1 month of blanking period indicated arrhythmia recurrence. Symptoms severity before ablation and during any recurrences was characterized by the Canadian Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF) score, and the score of atrial fibrillation related symptoms of the European Heart Rhythm Association (EHRA)."7

Statistical analysis

Patient characteristics and procedures, recurrence rates after a single procedure, and complication rates were compared according to the groups: LCT (case) or non-LCT (control). The sample size was determined by a 1: 4 ratio for cases and controls with study power of 80%.

Continuous variables were described as mean and standard deviation and compared using unpaired Student’s t-test (two-tailed), respecting the criteria of normality by Shapiro-Wilk test. Categorical variables were described by absolute number and percentages in relation to the total sample, and were compared using the χ² test or Fisher’s exact test. The level of statistical significance adopted was 5%. Kaplan-Meier curve was used to evidence the relapse-free rates over the follow-up time, and Log-Rank test was used to evaluate the difference between the groups (LCT x non-LCT). Statistical analysis was performed using IBM SPSS Statistics Editor software, version 22.0.
Results

One hundred and seventy-two patients were enrolled between 2011 and 2015 in a single center in Brazil. Thirty (17%) had LCT. There was no difference in follow-up time between cases and controls, with all patients completing a minimum follow-up of 12 months.

Table 1 summarizes the clinical characteristics of patients with LCT and non-LCT undergoing PAF ablation during the study. Variables such as age (58 ± 10 vs 62 ± 11 years), gender (71% vs 69% men), BMI (28 ± 4 vs 27 ± 3.5 kg/m²), LVEF (65 ± 8% vs 66 ± 9%), diameter of the left atrium (38 ± 5 mm vs. 39 ± 6 mm) presented no differences between the non-LCT and LCT groups, respectively. The prevalence of other comorbidities including hypertension, diabetes mellitus, coronary artery disease and risk score (CHA_{2}\text{D}_{2}-\text{VASc}) for stroke were similar among the samples. There was no significant difference in the severity of symptoms associated with AF (CCS-SAF and EHRA scores) between cases and controls. Four percent of the patients had a previous history of stroke.

Procedure efficacy and safety

Table 2 shows a relapse rate for AF of 27% and 10% in the non-LCT and LCT groups (OR: 3.4; p: 0.04), after a follow-up time of 34 ± 17 and 26 ± 15 months respectively for cases and controls. Kaplan-Meier curve (Figure 3) highlights the lower proportion of relapse in the LCT group during the study.

There were no major complications (TIA / stroke / Peripheral embolism, atrial-esophageal fistula or cardiac perforation / tamponade requiring surgery) related to procedures and or hospitalization. Among the minor complications (inguinal hematoma, retroperitoneal bleeding, pseudoaneurysms or AV fistulas, PV stenosis, pericardial effusions or phrenic nerve palsy) there were 4 pseudoaneurysms and 1 inguinal hematoma, all in the non-LCT group, treated clinically without surgical intervention (Table 2). There were no deaths or reports of esophageal fistula during the study follow-up time.

Discussion

The durability of PVs electrical isolation is directly related to the efficacy of the percutaneous treatment of AF, so that PVs electrical reconnection seems to be the main mechanism for post-ablation AF relapse.2,7-10 Our study suggests that pulmonary vein common left trunk patients have a more favorable clinical outcome after catheter ablation, with a clinical relapse around 10%. These results can be obtained without compromising procedure safety.

LCT, when present, has been indicated as the predominant origin of the triggers of AF.11 In the past, when the need for ablation of the 4 PV in the same procedure was still discussed, and maneuvers were used to trigger AF, some authors suggested that when AF originated in LCT, it was not necessary to perform right PV ablation.12,13 Over the years, this concept proved to be inadequate because some recurrences occurred from foci in the right PVs.2,8 For this reason, currently the information on the presence of the left common trunk helps more in the indication of the procedure rather than in the definition of the ablation strategy, which, unless otherwise indicated, will include the ablation of the LCT and the right PVs.
Table 1 – Clinical characteristics of patients undergoing AF ablation, categorization by presence of common trunk of the pulmonary veins

| Variables                        | n-LCT (n = 142) | LCT (n = 30) | p-value |
|----------------------------------|-----------------|--------------|---------|
| Age (years)                      | 58.1 ± 10       | 62.5 ± 11    | 0.11    |
| Gender (Male)                    | 101 (71)        | 20 (69.2)    | 0.64    |
| BMI                              | 27.6 ± 4.5      | 26.6 ± 3.5   | 0.37    |
| LV ejection fraction - %         | 64.4 ± 8.7 (33 – 86) | 66.2 ± 8.5 (46 – 77) | 0.33    |
| Diameter of the LA - mm          | 38 ± 5.2 (27 – 53) | 38.7 ± 6.3 (31 – 50) | 0.76    |

Comorbidities

|                  | n-LCT (n = 142) | LCT (n = 30) | p-value |
|------------------|-----------------|--------------|---------|
| SAH              | 82 (58.3)       | 18 (61.9)    | 0.75    |
| DM2              | 16 (11)         | 4 (13.3)     | 0.54    |
| CAD              | 30 (21)         | 4 (13.3)     | 0.63    |
| Prior Stroke/TIA | 6 (4.2)         | 1 (3.3)      | 0.86    |
| CCF              | 10 (7)          | 3 (10)       | 0.41    |
| CHA2DS2-VASc     | 1.49 ± 1.2      | 1.0 ± 1.9    | 0.49    |

AF - Symptoms

|                        | n-LCT (n = 142) | LCT (n = 30) | p-value |
|------------------------|-----------------|--------------|---------|
| CCS SAF score          | 2.07 ± 0.8      | 1.9 ± 0.8    | 0.46    |
| EHRA score             | 2.04 ± 0.3      | 2.1 ± 0.5    | 0.33    |

Medications

|                          | n-LCT (n = 142) | LCT (n = 30) | p-value |
|--------------------------|-----------------|--------------|---------|
| Statins                  | 41 (28)         | 12 (40)      | 0.12    |
| ACE or ARA Inhibitor     | 45 (31)         | 13 (42)      | 0.21    |
| Antiarrhythmic medication| 121 (85)        | 22 (73)      | 0.44    |

Values with ± indicate mean and standard deviation; BMI: body mass index; LV: left ventricle; LA: left atrium; SAH: systemic arterial hypertension; CAD: coronary artery disease; Stroke / TIA: stroke / transient ischemic attack; CCS SAF: Canadian Cardiovascular Society Severity of Atrial Fibrillation scale; EHRA: European Heart Rhythm Association; ACE: angiotensin converting enzyme; AF: atrial fibrillation; ARA: Angiotensin receptor antagonist 2. Student’s t test and χ² for independent samples. * p-value indicates a statistically significant difference at the level of 5%.

Table 2 – Efficacy of procedures and complications categorized by presence of left common trunk of the pulmonary veins

| Procedures          | n-LCT (n = 142) | LCT (n = 30) | OR   | p-value |
|---------------------|-----------------|--------------|------|---------|
| AF relapse          | 39 (27)         | 3 (10)       | 3.4  | 0.04*   |
| Follow-up time      | 34 ± 17         | 26 ± 15      | -    | 0.37    |

Complications

|                          | n-LCT (n = 142) | LCT (n = 30) | p-value |
|--------------------------|-----------------|--------------|---------|
| Pseudoaneurysm           | 4 (3)           | 0 (0)        | -      | 0.55    |
| Inguinal hematoma        | 1 (0.7)         | 0 (0)        | -      | 0.86    |

AF: atrial fibrillation; OR: Odds ratio; NA: not applicable; Student t test and χ² for independent samples. * p-value indicates a statistically significant difference at the level of 5%.

In the present case-control/single-centered study of patients undergoing the first ablation procedure for PAF, it is suggested that - in comparison to the standard anatomy - the presence of the LCT favors the results in the percutaneous treatment of AF, with lower recurrence rate and low complication rates in a long-term analysis. These findings highlight the importance of knowing PVs anatomy for the efficacy and safety of AF ablation.

The definition of LCT (approximately 20% of the sample) deserves discussion. In general, the diagnosis is quite simple, through detomography or cardiac resonance. In our study, we chose an unequivocal definition of common trunk, that is, when there was a minimum distance of 10 mm between the common ostium of the left PVs and the bifurcation of their left lower and upper branches. Thus, the diagnosis of LCT was intentionally simplified. This aspect has important clinical relevance. When identifying LCT, the clinical decision for catheter ablation can be simplified because the patient with this type of anatomical change has an excellent clinical result after ablation. In fact, there was no comparison between ablation and the use of antiarrhythmic drugs in this subgroup, but it is worth remembering that all patients ablated in our study were unresponsive to antiarrhythmic drugs.

This observation has an important practical effect. In clinical practice, it is not uncommon that patients with AF and anatomically normal heart by transthoracic echocardiography undergo numerous diagnostic tests. As a rule, these patients undergo multiple stress tests,
Figure 3 – Kaplan-Meier curves for AF relapse after catheter ablation categorized by the presence of the left common trunk of the pulmonary veins; Log-rank test for comparison of recurrence curves between groups (LCT vs n-LCT). p-value = 0.04. AF: atrial fibrillation; PV: pulmonary veins.

Limitations

The objective of this study was to describe the clinical characteristics and efficacy and safety outcomes in patients undergoing catheter ablation in the treatment of AF. This is a case-control study and, certainly, there are limitations. First, the sample size is small and may not be sufficient to detect differences between the two groups, particularly because of the low prevalence of LCT. Second, the presence of observation bias is recognized, since PVs anatomy is revealed during the procedure. Third, no detailed tool was used to assess symptoms in the presence of AF, but rather CCS-SAF and the EHRA score, which are generic scales for symptomatic evaluation. Despite this, the study provides an interesting perspective on the invasive treatment of AF in patients with LCT.

Conclusion

In our sample, patients with LCT who underwent the first catheter ablation procedure to treat PAF presented a lower rate of relapse compared to patients without this anatomical alteration. The research on LCT should be incorporated to the investigation of PAF patients because ablation is more effective in this group of patients.

Author contributions

Conception and design of the research, Acquisition of data, Critical revision of the manuscript for intellectual contente and Analysis and interpretation of the data: Odozynski G, Dal Forno ARJ, Lewandowski A, d’Avila A;
Statistical analysis, Obtaining financing e Writing of the manuscript: Odozynski G, d’Avila A.

Potential Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Sources of Funding
There were no external funding sources for this study.

References

1. Haïssaguerre M, Sanders P, Jaïs P, Clémenty J. Pulmonary veins in the substrate for atrial fibrillation: the “venous wave” hypothesis. J Am Coll Cardiol. 2004;43(12):2290-2.

2. Calkins H, Hindricks G, Cappato R, Kim Y, Saad EB, Aguinaga L, et al. 2017 HRS / EHRA / ECAS / APHRS / SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-444.

3. Verma A, Chen J, Betts TR, Deisenhofer I, Mantovan R, Ph D, et al; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812-22.

4. Marom EM, Herndon JE, Kim YH, Mcadams HP. Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation. Radiology. 2004;230(3):824-9.

5. Kanaji Y, Miyazaki S, Iwasawa J. Pre-procedural evaluation of the left atrial anatomy in patients referred for catheter ablation of atrial fibrillation. J Cardiol. 2016;67(1):115-21.

6. Prasanna LC, Praveena R, Souza AS, Bhat KM. Variations in the pulmonary venous ostium in the left atrium and its clinical importance. J Clin Diagn Res. 2014;8(2):10-1.

7. Dorian P, Guerra PG, Kerr CR, Donnell SS, Crystal E, Gillis AM, et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol. 2009;2(3):218-24.

8. Deuhner N, Greis H, Akkaya E, Berkowitz A, Zaltsberg S, Hamm CW, et al. Clinical experience with contact-force and flexible-tip ablation catheter designs. J Interv Card Electrophysiol. 2016;47(1):75-82.

9. Hunter RJ, Berriman TJ, Diabi I, Kamdar R, Richmond L, Goromonzi F, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7(1):31-8.

10. Ouyang F, Tilz R, Chun J, Schmidt B, Wisser E, Zerm T, et al. Long-term results of catheter ablation in paroxysmal: lessons from a 5-year follow-up. Circulation. 2010;122(3):2367-77.

11. Schwartzman D, Bazaz R, Nosbisch J. Common left pulmonary vein: a consistent source of arrhythmogenic atrial ectopy. J Cardiovasc Electrophysiol. 2004;15(5):565-6.

12. den Uijl DW, Tops LF, Delgado V, Schuijf JD, Kroft LJ, Roos A De, et al. Effect of pulmonary vein anatomy and left atrial dimensions on outcome of circumferential radiofrequency catheter ablation for atrial fibrillation. Am J Cardiol. 2011;107(2):243-9.

13. Woźniak-Skowierska I, Skowierski M, Wruck-wojar A, Hofmann A, Nowak S, Gola A, et al. Comparison of pulmonary veins anatomy in patients with and without atrial fibrillation: analysis by multislice tomography. Int J Cardiol. 2013;164(2):183-5.

14. McLellan AJ, Ling L, Ruggiero D, Wong MC, Walters TE, Nisbet A, et al. Pulmonary vein isolation: the impact of pulmonary venous anatomy on long-term outcome of catheter ablation for paroxysmal atrial fibrillation. Heart Rhythm. 2014;11(4):549-56.

15. Scharf C, Sneider M, Case IA, Chugh A, Lai SW, Pelosi F, et al. Anatomy of the pulmonary veins in patients with atrial fibrillation and effects of segmental ostial ablation analyzed by computed tomography. J Cardiovasc Electrophysiol. 2003;14(2):150-5.

16. Makimoto H, Lin T, Rillig A, Metzner A, Wohlmuth P, Arya A, et al. In vivo contact force analysis and correlation and catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(1):46-54.

17. Shurrab M, Di Biase L, Briceno DF, Kaoutskaia A, Haj-Yahia S, Newman D, et al. Impact of contact force technology on atrial fibrillation ablation: a meta-analysis. J Am Heart Assoc. 2015;4(9):e002476.

18. Heeger C, Tscholl V, Wisser E, Fink T, Rottner L, Wohlmuth P, et al. Acute efficacy, safety, and long-term clinical outcomes using the second-generation cryoballoon for pulmonary vein isolation in patients with a left common pulmonary vein: a multicenter study. Hear Rhythm. 2017;14(8):1111-8.

Study Association
This study is not associated with any thesis or dissertation work.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Universidade Federal de Santa Catarina under the protocol number 45509015600000121. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.

Arq Bras Cardiol. 2018; 111(6):824-830
